Results 171 to 180 of about 12,515 (211)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia. [PDF]

Front Pharmacol, 2020
Chen Y, Dong X, Wang Q, Liu Z, Dong X, Shi S, Xiao H.   +6 more
europepmc   +1 more source

Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line. [PDF]

Purinergic Signal, 2020
Willig JB, Vianna DRB, Beckenkamp A, Beckenkamp LR, Sévigny J, Wink MR, Buffon A, Pilger DA.   +7 more
europepmc   +1 more source

Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro. [PDF]

Oncol Lett, 2019
Kroschwald LM, Tauer JT, Kroschwald SI, Suttorp M, Wiedenfeld A, Beissert S, Bauer A, Rauner M.   +7 more
europepmc   +1 more source

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

, 2004
Shinya Kimura, Junya Kuroda, Taira Maekawa   +2 more
openalex   +2 more sources

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. [PDF]

Sci Rep, 2019
Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA.   +17 more
europepmc   +1 more source

Imatinib Mesylate [PDF]

Drugs, 2003
Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and platelet-derived growth factor receptors. The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no
Caroline M. Perry, Katherine F Croom
  +6 more sources

Dysregulation of bone remodeling by imatinib mesylate [PDF]

Blood, 2010
AbstractImatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the efficacy and tolerability of imatinib are a vast improvement over conventional chemotherapies, the drug exhibits off-target effects. An unanticipated side effect
Vandyke, K., Fitter, S., Dewar, A., Hughes, T., Zannettino, A.   +4 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Effects of imatinib mesylate in osteoblastogenesis

Experimental Hematology, 2009
Imatinib mesylate (IM), a tyrosine kinase inhibitor currently used in chronic myeloid leukemia (CML), may also affect the growth of other cellular systems besides CML cells. Because it has been reported that IM may affect bone tissue remodeling, we evaluated the effects of IM on osteoblastic differentiation of human bone marrow mesenchymal stem cells ...
TIBULLO D, GIALLONGO C, LA CAVA P, BERRETTA S, STAGNO F, CHIARENZA A, CONTICELLO C, PALUMBO GA, DI RAIMONDO, FRANCESCO   +8 more
openaire   +3 more sources

An evaluation of the cardiotoxicity of imatinib mesylate

Leukemia Research, 2008
We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and ...
Antonio Luiz Pinho Ribeiro, Vitor Fonseca Xavier, Maria do Carmo Pereira Nunes, Henrique Bittencourt, Milena Soriano Marcolino, Nelma Cristina D. Clementino, Marcia M. Barbosa   +6 more
openaire   +3 more sources

Another Look at Imatinib Mesylate

New England Journal of Medicine, 2006
Imatinib mesylate may affect particular signaling pathways that increase susceptibility to congestive heart failure.
Axel Ullrich, Klaus Strebhardt
openaire   +3 more sources